Volume 2: Issue 2
pp71-204
 |
About the CoverThe cover for the issue of Oncoscience features Figure 2 (“SapC-DOPS nanovesicles: a novel targeted agent for the imaging and treatment of glioblastoma”) from Blanco et al. |
News
Editorials
Functional polymorphisms in cancer
https://doi.org/10.18632/oncoscience.129
Divyansh Agarwal, Christos Hatzis, Lajos Pusztai
p 73-74
TIC10/ONC201: a bend in the road to clinical development
https://doi.org/10.18632/oncoscience.133
Yoshimi Endo Greer, Stanley Lipkowitz
p 75-76
BCC or not: Sufu keeps it in check
https://doi.org/10.18632/oncoscience.134
Wen-Chi Yin, Zhu Juan Li, Chi-chung Hui
p 77-78
Fighting Neuroblastomas with NBAT1
https://doi.org/10.18632/oncoscience.126
Gaurav Kumar Pandey, Chandrasekhar Kanduri
p 79-80
Reviews
Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies
https://doi.org/10.18632/oncoscience.130
Kimryn W. Rathmell, Fengju Chen, Chad J. Creighton
p 81-90
Abstract | PDF | Full Text | How to Cite
Research Perspectives
Two preclinical tests to evaluate anticancer activity and to help validate drug candidates for clinical trials
https://doi.org/10.18632/oncoscience.132
Miguel López-Lázaro
p 91-98
PDF | Full Text | How to Cite
MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments
https://doi.org/10.18632/oncoscience.135
Mariska Miranda, Esdy Rozali, Kum Kum Khanna, Fares Al-Ejeh
p 99-101
PDF | Full Text | How to Cite
SapC-DOPS nanovesicles: a novel targeted agent for the imaging and treatment of glioblastoma
https://doi.org/10.18632/oncoscience.122
Víctor M. Blanco, Richard Curry, Xiaoyang Qi
p 102-110
PDF | Full Text | How to Cite
Research Papers
Genistein exerts anti-leukemic effects on genetically different acute myeloid leukemia cell lines by inhibiting protein synthesis and cell proliferation while inducing apoptosis – molecular insights from an iTRAQ™ quantitative proteomics study
https://doi.org/10.18632/oncoscience.120
Karthik Narasimhan, Yew Mun Lee, Teck Kwang Lim, Sarah Alexandra Port, Jin-Hua Han, Chien-Shing Chen, Qingsong Lin
p 111-124
Abstract | PDF | Full Text | Supplementary Materials | Supplementary Table | How to Cite
RAS mutations vary between lesions in synchronous primary Colorectal Cancer: Testing only one lesion is not sufficient to guide anti-EGFR treatment decisions.
https://doi.org/10.18632/oncoscience.118
Mariana Petaccia de Macedo, Fernanda Machado de Melo, Júlia da Silva Ribeiro, Celso Abdon Lopes de Mello, Maria Dirlei Ferreira de Souza Begnami, Fernando Augusto Soares, Dirce Maria Carraro , Isabela Werneck da Cunha
p 125-130
Abstract | PDF | Full Text | How to Cite
Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival
https://doi.org/10.18632/oncoscience.119
Esther Martínez-Martínez, Irene Gómez, Paloma Martín, Antonio Sánchez, Laura Román, Eva Tejerina, Félix Bonilla , Antonio García Merino, Antonio García de Herreros, Mariano Provencio, Jose M. García
p 131-141
Abstract | PDF | Full Text | How to Cite
TR4 nuclear receptor enhances prostate cancer initiation via altering the stem cell population and EMT signals in the PPARG-deleted prostate cells
https://doi.org/10.18632/oncoscience.121
Shin-Jen Lin, Dong-Rong Yang, Nancy Wang, Ming Jiang, Hiroshi Miyamoto, Gonghui Li, Chawnshang Chang
p 142-150
Abstract | PDF | Full Text | Supplementary Materials | How to Cite
Analysis and interpretation of transcriptomic data obtained from extended Warburg effect genes in patients with clear cell renal cell carcinoma
https://doi.org/10.18632/oncoscience.128
Edward Sanders, Svenja Diehl
p 151-186
Abstract | PDF | Full Text | Supplementary Materials | Supplementary Table | How to Cite
Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations
https://doi.org/10.18632/oncoscience.131
Jorge Galvez Silva, Fernando F. Corrales-Medina, Ossama M. Maher, Nizar Tannir, Winston W. Huh, Michael E. Rytting, Vivek Subbiah
p 187-192
Abstract | PDF | Full Text | How to Cite
Versican is a potential therapeutic target in docetaxel-resistant prostate cancer
https://doi.org/10.18632/oncoscience.136
Naoko Arichi, Yozo Mitsui, Miho Hiraki, Sigenobu Nakamura, Takeo Hiraoka, Masahiro Sumura, Hiroshi Hirata, Yuichiro Tanaka, Rajvir Dahiya, Hiroaki Yasumoto, Hiroaki Shiina
p 193-204
Abstract | PDF | Full Text | Supplementary Materials | How to Cite